journal
https://read.qxmd.com/read/39030183/genomic-and-immune-determinants-of-resistance-to-daratumumab-based-therapy-in-relapsed-refractory-multiple-myeloma
#1
JOURNAL ARTICLE
Bachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Elisa Genuardi, Marios Papadimitriou, Benjamin Diamond, Paolo Corradini, David Coffey, Ola Landgren, Niccolò Bolli, Benedetto Bruno, Mario Boccadoro, Massimo Massaia, Francesco Maura, Alessandra Larocca
Targeted immunotherapy combinations, including the anti-CD38 monoclonal antibody (MoAb) daratumumab, have shown promising results in patients with relapsed/refractory multiple myeloma (RRMM), leading to a considerable increase in progression-free survival. However, a large fraction of patients inevitably relapse. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676). We conducted an integrated analysis using whole-genome sequencing (WGS) and flow cytometry in patients with RRMM...
July 19, 2024: Blood Cancer Journal
https://read.qxmd.com/read/39030163/myeloid-neoplasms-arising-after-methotrexate-therapy-for-autoimmune-rheumatological-diseases-do-not-exhibit-poor-risk-molecular-features
#2
LETTER
Mihir D Wechalekar, Lin-Pierre Zhao, Monika M Kutyna, Lih En Hong, Joule Li, Kevin Hung, Hamish S Scott, Anna Brown, Christopher C Hahn, Karin Kassahn, Dariusz Ladon, David T Yeung, Daniel Thomas, Mrinal Patnaik, Susanna Proudman, Lionel Ades, Mithun V Shah, Chung H Kok, Devendra K Hiwase
No abstract text is available yet for this article.
July 19, 2024: Blood Cancer Journal
https://read.qxmd.com/read/39019891/long-term-responders-in-frontline-multiple-myeloma-exception-vs-expectation-of-the-modern-era
#3
LETTER
Muhamed Baljevic, Douglas W Sborov, Shaji K Kumar
No abstract text is available yet for this article.
July 17, 2024: Blood Cancer Journal
https://read.qxmd.com/read/39013866/using-mendelian-randomisation-to-search-for-modifiable-risk-factors-influencing-the-development-of-clonal-haematopoiesis
#4
LETTER
Jessica M Hislop, Molly Went, Charlie Mills, Amit Sud, Philip J Law, Richard S Houlston
No abstract text is available yet for this article.
July 16, 2024: Blood Cancer Journal
https://read.qxmd.com/read/39009567/improved-prevention-and-treatment-strategies-for-differentiation-syndrome-contribute-to-reducing-early-mortality-in-patients-with-acute-promyelocytic-leukemia
#5
LETTER
Qian Wu, Xiaofei Yang, Jingren Zhang, Mengxing Xue, Xueqing Dou, Zheng Ge, Yifei Chen, Weiying Gu, Weimin Dong, Hongying Cao, Naike Jiang, Xuemei Sun, Zefa Liu, Jinning Shi, Hui Chen, Cixian Zhang, Fengling Min, Hongli Sun, Xiaoli Qian, Hongjian Yuan, Yuan Feng, De-Pei Wu, Suning Chen
No abstract text is available yet for this article.
July 15, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38997261/prognostic-and-therapeutic-implications-of-tp53-expression-in-chronic-myelomonocytic-leukemia
#6
LETTER
Yu-Hung Wang, Chien-Chin Lin, Kristian Gurashi, Chi-Yuan Yao, Andres Jerez, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien, Kiran Batta, Daniel H Wiseman
No abstract text is available yet for this article.
July 12, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38987557/immune-dysfunction-prior-to-and-during-vaccination-in-multiple-myeloma-a-case-study-based-on-covid-19
#7
JOURNAL ARTICLE
Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, Anastasiia Zherniakova, Aintzane Zabaleta, Catarina Maia, Laura Blanco, Diego Alignani, Maria-Antonia Fortuño, Carlos Grande, Andrea Manubens, Jose-Maria Arguiñano, Clara Gomez, Ernesto Perez-Persona, Iñigo Olazabal, Itziar Oiartzabal, Carlos Panizo, Felipe Prosper, Jesus F San-Miguel, Paula Rodriguez-Otero, Bruno Paiva
Infection is the leading cause of death in multiple myeloma (MM). However, the cellular composition associated with immune dysfunction is not defined. We analyzed immune profiles in the peripheral blood of patients with MM (n = 28) and B-cell chronic lymphoproliferative disorders (n = 53) vs. health care practitioners (n = 96), using multidimensional and computational flow cytometry. MM patients displayed altered distribution of most cell types (41/56, 73%), particularly within the B-cell (17/17) and T-cell (20/30) compartments...
July 10, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38977707/daratumumab-in-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-final-analysis-of-clinically-relevant-subgroups-in-griffin
#8
RANDOMIZED CONTROLLED TRIAL
Ajai Chari, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Peter M Voorhees, Saad Z Usmani, Paul G Richardson
The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up, 49.6 months) of clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities (HRCAs) per revised definition (del[17p], t[4;14], t[14;16], t[14;20], and/or gain/amp[1q21]). Patients received 4 induction cycles (D-RVd/RVd), high-dose therapy/transplant, 2 consolidation cycles (D-RVd/RVd), and lenalidomide±daratumumab maintenance (≤ 2 years)...
July 8, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38977689/efficacy-of-blinatumomab-as-maintenance-therapy-for-b-lineage-acute-lymphoblastic-leukemia-lymphoma-following-allogeneic-hematopoietic-cell-transplantation
#9
LETTER
Jiayu Huang, Bingyang Shi, Suhui Yu, Mengxing Xue, Ling Wang, Jieling Jiang, Jiong Hu, Jun Zhu, Suning Chen, Lijing Shen, Weijie Cao, Yang Cao, Xiaoxia Hu
No abstract text is available yet for this article.
July 8, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38977682/autologous-transplant-vs-car-t-therapy-in-patients-with-dlbcl-treated-while-in-complete-remission
#10
COMPARATIVE STUDY
Mazyar Shadman, Kwang W Ahn, Manmeet Kaur, Lazaros Lekakis, Amer Beitinjaneh, Madiha Iqbal, Nausheen Ahmed, Brian Hill, Nasheed M Hossain, Peter Riedell, Ajay K Gopal, Natalie Grover, Matthew Frigault, Jonathan Brammer, Nilanjan Ghosh, Reid Merryman, Aleksandr Lazaryan, Ron Ram, Mark Hertzberg, Bipin Savani, Farrukh Awan, Farhad Khimani, Sairah Ahmed, Vaishalee P Kenkre, Matthew Ulrickson, Nirav Shah, Mohamed A Kharfan-Dabaja, Alex Herrera, Craig Sauter, Mehdi Hamadani
In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a CR. A retrospective observational study comparing auto-HCT (2015-2021) vs. CAR-T (2018-2021) using the Center for International Blood & Marrow Transplant Research registry. Median follow-up was 49.7 months for the auto-HCT and 24...
July 8, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38977668/improving-outcomes-with-anti-bcma-bispecific-antibodies-with-attention-to-infection
#11
LETTER
Andrew J Yee
No abstract text is available yet for this article.
July 8, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38969655/hematopoietic-stem-cell-transplantation-for-dlbcl-a-report-from-the-european-society-for-blood-and-marrow-transplantation-on-more-than-40-000-patients-over-32-years
#12
JOURNAL ARTICLE
Philipp Berning, Mathilde Fekom, Maud Ngoya, Anthony H Goldstone, Peter Dreger, Silvia Montoto, Hervé Finel, Evgenii Shumilov, Patrice Chevallier, Didier Blaise, Tim Strüssmann, Ben Carpenter, Edouard Forcade, Cristina Castilla-Llorente, Marek Trneny, Hervé Ghesquieres, Saveria Capria, Catherine Thieblemont, Igor Wolfgang Blau, Ellen Meijer, Annoek E C Broers, Anne Huynh, Denis Caillot, Wolf Rösler, Stephanie Nguyen Quoc, Jörg Bittenbring, Arnon Nagler, Jacques-Emmanuel Galimard, Bertram Glass, Anna Sureda, Norbert Schmitz
Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined the transplantation trends and outcomes for DLBCL patients undergoing auto-/allo-HSCT between 1990 and 2021 reported to EBMT. Over this period, 41,148 patients underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a maximum of 294 cases in 2018...
July 5, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38965209/patient-specific-computational-models-predict-prognosis-in-b-cell-lymphoma-by-quantifying-pro-proliferative-and-anti-apoptotic-signatures-from-genetic-sequencing-data
#13
JOURNAL ARTICLE
Richard Norris, John Jones, Erika Mancini, Timothy Chevassut, Fabio A Simoes, Chris Pepper, Andrea Pepper, Simon Mitchell
Genetic heterogeneity and co-occurring driver mutations impact clinical outcomes in blood cancers, but predicting the emergent effect of co-occurring mutations that impact multiple complex and interacting signalling networks is challenging. Here, we used mathematical models to predict the impact of co-occurring mutations on cellular signalling and cell fates in diffuse large B cell lymphoma and multiple myeloma. Simulations predicted adverse impact on clinical prognosis when combinations of mutations induced both anti-apoptotic (AA) and pro-proliferative (PP) signalling...
July 4, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38926354/correction-to-preclinical-studies-of-flonoltinib-maleate-a-novel-jak2-flt3-inhibitor-in-treatment-of-jak2-v617f-induced-myeloproliferative-neoplasms
#14
Mengshi Hu, Tao Yang, Linyu Yang, Lu Niu, Jinbing Zhu, Ailin Zhao, Mingsong Shi, Xue Yuan, Minghai Tang, Jianhong Yang, Heying Pei, Zhuang Yang, Qiang Chen, Haoyu Ye, Ting Niu, Lijuan Chen
No abstract text is available yet for this article.
June 26, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38918372/are-thrombosis-progression-and-survival-in-et-predictable
#15
LETTER
Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Ahamed Lebbe, Imane Bouhali, Mohammed Khalid, Richard T Silver, Joseph M Scandura
No abstract text is available yet for this article.
June 25, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38914584/prognostic-implications-of-%C3%AE-np73-tap73-expression-ratio-in-core-binding-factor-acute-myeloid-leukemia
#16
LETTER
Maria L Salustiano-Bandeira, Amanda Moreira-Aguiar, Diego A Pereira-Martins, Juan L Coelho-Silva, Isabel Weinhäuser, Pedro L França-Neto, Aleide S Lima, Ana S Lima, Anemari R Baccarin, Fernanda B Silva, Manuela A de Melo, Fernanda S Niemann, Luciana Nardinelli, César A Ortiz Rojas, Bruno K Duarte, Aderson S Araujo, Elisa A Azevedo, Clarice N Morais, Lorena L Figueiredo-Pontes, Jan J Schuringa, Gerwin Huls, Israel Bendit, Eduardo M Rego, Sara T Olalla Saad, Fabiola Traina, Marcos A Bezerra, Antonio R Lucena-Araujo
No abstract text is available yet for this article.
June 24, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38902256/multiomic-analysis-identifies-a-high-risk-signature-that-predicts-early-clinical-failure-in-dlbcl
#17
JOURNAL ARTICLE
Kerstin Wenzl, Matthew E Stokes, Joseph P Novak, Allison M Bock, Sana Khan, Melissa A Hopper, Jordan E Krull, Abigail R Dropik, Janek S Walker, Vivekananda Sarangi, Raphael Mwangi, Maria Ortiz, Nicholas Stong, C Chris Huang, Matthew J Maurer, Lisa Rimsza, Brian K Link, Susan L Slager, Yan Asmann, Patrizia Mondello, Ryan Morin, Stephen M Ansell, Thomas M Habermann, Thomas E Witzig, Andrew L Feldman, Rebecca L King, Grzegorz Nowakowski, James R Cerhan, Anita K Gandhi, Anne J Novak
Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet need, we used an integrative multiomic approach to identify a signature at diagnosis that will identify DLBCL at high risk of early clinical failure. Tumor biopsies from 444 newly diagnosed DLBCL were analyzed by WES and RNAseq. A combination of weighted gene correlation network analysis and differential gene expression analysis was used to identify a signature associated with high risk of early clinical failure independent of IPI and COO...
June 20, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38902249/clinical-features-and-outcomes-in-primary-nervous-system-histiocytic-neoplasms
#18
LETTER
Nabeela Nathoo, Joon H Uhm, Alyx B Porter, Julie Hammack, Kurt A Jaeckle, Maciej M Mrugala, Brian A Crum, Eoin P Flanagan, Sean J Pittock, Gaurav Goyal, Jason R Young, Matthew J Koster, Robert Vassallo, Jay H Ryu, Caroline J Davidge-Pitts, Corrie Bach, Aishwarya Ravindran, Julio C Sartori Valinotti, N Nora Bennani, Jithma P Abeykoon, Mithun V Shah, C Christopher Hook, Karen L Rech, Ronald S Go, W Oliver Tobin
No abstract text is available yet for this article.
June 20, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38890297/real-world-predictors-of-response-and-24-month-survival-in-high-grade-tp53-mutated-myeloid-neoplasms
#19
JOURNAL ARTICLE
Amandeep Kaur, Alexandra E Rojek, Emily Symes, Mariam T Nawas, Anand A Patel, Jay L Patel, Payal Sojitra, Barina Aqil, Madina Sukhanova, Megan E McNerney, Leo P Wu, Aibek Akmatbekov, Jeremy Segal, Melissa Y Tjota, Sandeep Gurbuxani, Jason X Cheng, Su-Yeon Yeon, Harini V Ravisankar, Carrie Fitzpatrick, Angela Lager, Michael W Drazer, Caner Saygin, Pankhuri Wanjari, Panagiotis Katsonis, Olivier Lichtarge, Jane E Churpek, Sharmila B Ghosh, Ami B Patel, Madhu P Menon, Daniel A Arber, Peng Wang, Girish Venkataraman
Current therapies for high-grade TP53-mutated myeloid neoplasms (≥10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve a complete response to first line therapy (CR1). To identify reliable pre-therapy predictors of complete response to first-line therapy (CR1) and outcomes, we assembled a cohort of 242 individuals with TP53-mutated myeloid neoplasms and ≥10% blasts with well-annotated clinical, molecular and pathology data...
June 18, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38890292/anti-cd5-car-t-cells-with-a-tegfr-safety-switch-exhibit-potent-toxicity-control
#20
LETTER
Haolong Lin, Jiali Cheng, Li Zhu, Yuhao Zeng, Zhenyu Dai, Yicheng Zhang, Xiaojian Zhu, Wei Mu
No abstract text is available yet for this article.
June 18, 2024: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.